Exelixis | EXEL - Interest Income


Exelixis reported $15.92M in Interest Income for its fiscal quarter ending in September of 2025.





Interest Income Change Date
Acadia Pharmaceuticals USD 8.25M 1M Sep/2025
Agios Pharmaceuticals USD 13.37M 1.14M Sep/2025
AstraZeneca USD 85M 17M Sep/2025
Bayer EUR 130M 38M Sep/2025
BioMarin Pharmaceutical USD 17.85M 973K Sep/2025
Cytokinetics USD 10.25M 2.75M Sep/2025
Eisai JPY 3.11B 783M Mar/2024
Eli Lilly USD 65M 25M Sep/2025
Esperion Therapeutics USD -0.15 0.18 Sep/2024
Exelixis USD 15.92M 867K Sep/2025
Genmab DKK 25M 8M Jun/2025
Glaxosmithkline GBP 26M 24M Sep/2025
Incyte USD 30.75M 3.97M Dec/2025
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
MacroGenics USD 1.53M 114K Sep/2025
Merck USD 96M 27M Sep/2025
Moderna USD 73M 8M Sep/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Pfizer USD 0.62 156M Sep/2025
Puma Biotechnology USD 0.41 0.5 Sep/2024
Sanofi EUR 114M 38M Sep/2025
Takeda JPY 87.87B 43.48B Dec/2025
Ultragenyx Pharmaceutical USD 5.86M 69K Sep/2025
Xencor USD 6.54M 710K Sep/2025